DP-R208 Pharmacokinetic Study

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R208 (Candesartan cilexetil 8mg/Rosuvastatin 10mg), a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alvogen Korea
• Treatments: Candesartan; Candesartan cilexetil; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• BMI 18~30

• signed the informed consent form prior to the study participation

Exclusion Criteria:

• Clinically significant disease

• Previously donate whole blood within 60 days or component blood within 14 days

• Clinically significant allergic disease

• Taken IP in other trial within 90 days

• An impossible one who participates in clinical trial by investigator's decision including laboratory test result